ArticleEuropean journal of hospital pharmacy : science and practice2020

Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain.

Cristina Trigo-Vicente et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.